Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 16Completed 12Unknown 9Active not recruiting 5Terminated 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 6OTHER 2NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Breast Neoplasms 723Neoplasms 461Prostatic Neoplasms 398Carcinoma, Non-Small-Cell Lung 388Lung Neoplasms 311Leukemia, Myeloid, Acute 301Multiple Myeloma 270Colorectal Neoplasms 243Neoplasm Metastasis 240Pancreatic Neoplasms 238Leukemia 235Melanoma 217Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 195Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 174Myelodysplastic Syndromes 168Leukemia, Lymphocytic, Chronic, B-Cell 168Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 116Squamous Cell Carcinoma of Head and Neck 109

Interventions

pembrolizumab 1antineoplaston AS 2-1 1antineoplaston A10 1Mitotane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Adrenocortical Carcinoma × Clear all
NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT00003453 2018-05-09

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Burzynski Research Institute

Phase 2 Terminated
6 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡